Healthcare ETFs: FHLC vs. IYH - The Real Question Isn't Which Issuer Wins

The headline question is the wrong one. "Should you buy the Fidelity or iShares healthcare ETF?" is a marketing prompt, not an investment question. The question the factor stack actually answers is whether the healthcare sector - now trading near the expensive end of its own history - deserves a new position at all, and if so, which fund structure earns the job.

Healthcare posted 0.3% in 2023, 0.9% in 2024, and 12.5% in 2025 while the S&P 500 moved ahead on AI enthusiasm and rate-cut optimism. Three years of underperformance. Then, in 2026, the sector finally turned. Year-to-date as of late February 2026, healthcare returns were modestly above the S&P 500. Trailing twelve months through late July, the sector posted 21.3% - respectably strong, even if still below technology and energy. Biotech led the turnaround with improving clinical trial success rates and a pickup in M&A and IPO activity. Managed care is digesting higher medical costs. Policy overhangs - including drug pricing proposals - have softened after Pfizer's September 2025 agreement with the administration set a precedent.

The performance inflection is real. The valuation context is less flattering. The S&P 500 Health Care sector P/E sits at 29.43 as of late July 2026. The five-year average is 24.74. The ten-year average is 21.04. The current reading is more than one standard deviation above the five-year mean and well above the ten-year mean. By the standard z-score framework, this is overvalued on a medium-to-long horizon. That doesn't mean the trade is dead - it means the margin for error is thinner than it was twelve months ago when the sector looked genuinely cheap.

So which ETF, if any, matches the job? Let's walk through the three most relevant vehicles.

1. FHLC - Fidelity MSCI Health Care Index ETF

Expense ratio:0.08% - Holdings: ~342 - AUM: ~$3.2B - Beta:0.62

FHLC tracks the MSCI USA IMI Health Care Index, which captures large-, mid-, and small-cap healthcare companies across the U.S. market. That's roughly 342 holdings, with Eli Lilly (13.8%), Johnson & Johnson (8.6%), and AbbVie (6.1%) anchoring the top.

On cost, this is the clear winner. An 8-basis-point expense ratio is virtually free for broad sector exposure - and the 30-basis-point spread versus IYH compounds to roughly $300 in extra drag per $100,000 invested, every year, in perpetuity. FHLC also has a slightly higher dividend yield (1.40% vs. IYH's 1.28%) because its small- and mid-cap slice tilts the distribution mix toward pharma and med-tech dividend payers.

Portfolio role: This is the default healthcare sleeve when you want full-cap coverage at the lowest cost. The small-cap exposure gives it a slight growth kicker if the biotech and med-device tail continues to recover. But it also means more idiosyncratic risk from names that trade thinly.

What would change the view: A broad market correction would pressure the small-cap holdings harder than the large-cap-only funds, given their lower liquidity and higher beta to biotech sentiment.

2. IYH - iShares U.S. Healthcare ETF

Expense ratio: 0.38% - Holdings: 101 - AUM: ~$3.1B - Beta: 0.57

IYH tracks the Russell 1000 Health Care RIC 22.5/45 Capped Index. It holds 101 stocks, primarily large-cap blue chips. The top three - Lilly (15.8%), J&J (9.7%), AbbVie (6.9%) - are the same names as FHLC but at slightly higher weights because IYH has no small-cap layer to dilute them.

The fund earned a Morningstar Bronze rating as of June 30, 2026, against 159 health funds. Its one-year total return as of June 30, 2026, was 20.20%, versus 20.62% for its benchmark. That's close tracking, but the question is whether you're paying 38 basis points to get it.

Here's the problem from a comparison standpoint: IYH charges 38 bps - nearly five times FHLC's rate - for a product that is less diversified (101 holdings vs. 342), slightly more concentrated in the top names, and has not meaningfully outperformed FHLC. The 1-year return as of June 12, 2026, was approximately 14% for IYH versus 16% for FHLC. You're paying more to get less diversification and lower returns.

Portfolio role: Only if you specifically want a large-cap-only, moderately concentrated healthcare exposure and don't care about the expense ratio differential. I can't find a factor-based reason to prefer IYH over FHLC for most investors.

What would change the view: A sustained outperformance of large-cap pharma over small/mid-cap healthcare that materially closes the return gap while the expense differential stops mattering relative to alpha. That hasn't happened, and the structural cost disadvantage persists.

3. XLV - State Street Health Care Select Sector SPDR ETF

Holdings: 62 - Beta:0.56 - YTD return (late July): 6.53%

XLV didn't make the original Fidelity-vs.-iShares question, but it deserves a spot in the comparison set. It's the largest and most liquid healthcare ETF by assets. Its 62 holdings are almost entirely large-cap (98.4%), with the top 10 names accounting for 61.5% of assets. That's concentrated. A one-year return of 23.98% through late July, versus the category average of 36.17%, suggests XLV has lagged the broader healthcare-ETF category - likely because its S&P 500–only universe misses the small-cap biotech names that powered the sector's 2026 recovery.

Portfolio role: Short-term rotation trades and institutional flows where liquidity and tight spreads matter more than cost or diversification. Not the hold-and-accumulate vehicle for most retail investors.

What the sector valuation means for entry

The healthcare sector isn't cheap anymore. That P/E of 29.43 - above the five-year average of 24.74 and the ten-year average of 21.04 - means the market has already priced in a fair amount of the turnaround story. The policy overhang easing, the biotech recovery, the M&A wave: much of it is in the price.

That doesn't make healthcare a sell. It makes it a hold-and-add-on-dips setup, not a full-allocation rush. A sector that trailed for three years doesn't deserve punishment for finally catching up, but neither does it deserve conviction buying at the top of its valuation range.

Bottom line

If you're adding healthcare exposure now:

• FHLC is the structural winner. Lowest cost (0.08%), broadest diversification (~342 holdings including small-cap), slightly higher yield. It's the vehicle that works whether the sector continues to grind higher or pauses.
• IYH is harder to justify. It costs 38 bps, holds fewer stocks, and hasn't outperformed. The expense differential is the single clearest decision point in this comparison.
• XLV is the liquidity trade. Fine for rotation or tactical tilts, not for patient capital.

The watchpoint going forward is whether that P/E of 29.43 holds or starts to compress. If earnings growth in pharma and biotech continues to run at the pace investors are pricing in, the multiple sustains itself. If the pipeline disappoints or drug pricing policy resurfaces with force, the sector could give back some of this year's gains. That's the risk that makes dollar-cost averaging into FHLC a more sensible entry than one-and-done sizing.

Narratives about healthcare "finally turning" are correct but incomplete. The factor stack says the sector has recovered from cheap to expensive. The fund comparison says the cheapest, most diversified vehicle wins by a wide margin. Combine those two facts and the answer becomes clearer.